应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
休市中 12-05 16:00:00 EST
90.18
+0.15
+0.17%
盘后
90.41
+0.23
+0.26%
19:00 EST
最高
91.18
最低
90.07
成交量
543.29万
今开
90.69
昨收
90.03
日振幅
1.24%
总市值
2,797亿
流通市值
2,785亿
总股本
31.01亿
成交额
4.92亿
换手率
0.18%
流通股本
30.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
港股异动 | 和铂医药-B(02142)午后涨近4% 公司与阿斯利康深化推进全球战略合作
智通财经 · 12-02
港股异动 | 和铂医药-B(02142)午后涨近4% 公司与阿斯利康深化推进全球战略合作
港股异动 | 和铂医药-B(02142)再涨超4% 与阿斯利康深化合作 共同研发新一代肿瘤生物疗法
智通财经 · 11-27
港股异动 | 和铂医药-B(02142)再涨超4% 与阿斯利康深化合作 共同研发新一代肿瘤生物疗法
阿斯利康投资20亿美元用于美国生物制品生产，同时RSV疫苗持久性与阿尔茨海默病药物试验面临挑战AstraZeneca Invests $2 Billion in US Biologics Manufacturing as RSV Vaccine Durability and Alzheimer’s Drug Trials Face Challenges
动脉网 · 11-25
阿斯利康投资20亿美元用于美国生物制品生产，同时RSV疫苗持久性与阿尔茨海默病药物试验面临挑战AstraZeneca Invests $2 Billion in US Biologics Manufacturing as RSV Vaccine Durability and Alzheimer’s Drug Trials Face Challenges
港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法
智通财经 · 11-25
港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法
阿斯利康：将在马里兰州投资20亿美元扩大美国业务
环球市场播报 · 11-24
阿斯利康：将在马里兰州投资20亿美元扩大美国业务
和铂医药：与阿斯利康深化合作，共同研发新一代肿瘤生物疗法
南方财经网 · 11-24
和铂医药：与阿斯利康深化合作，共同研发新一代肿瘤生物疗法
和铂医药-B与 AstraZeneca修订合作协议 合作范围进一步扩展
智通财经 · 11-24
和铂医药-B与 AstraZeneca修订合作协议 合作范围进一步扩展
阿斯利康宣布投资20亿美元扩建马里兰州生产基地
格隆汇 · 11-22
阿斯利康宣布投资20亿美元扩建马里兰州生产基地
阿斯利康盘中异动 大幅上涨3.01%
市场透视 · 11-22
阿斯利康盘中异动 大幅上涨3.01%
阿斯利康旗下Koselugo获美国FDA批准用于成人Ⅰ型神经纤维瘤病治疗
环球市场播报 · 11-21
阿斯利康旗下Koselugo获美国FDA批准用于成人Ⅰ型神经纤维瘤病治疗
巩固英股“第一大权重股”地位，医药巨头阿斯利康股价创新高
华尔街见闻 · 11-11
巩固英股“第一大权重股”地位，医药巨头阿斯利康股价创新高
阿斯利康股价再创新高 涨超2%
每日经济新闻 · 11-11
阿斯利康股价再创新高 涨超2%
阿斯利康(AZN)盘前升1.54% baxdrostat临床试验达成主要和次要研究目标
金吾财讯 · 11-10
阿斯利康(AZN)盘前升1.54% baxdrostat临床试验达成主要和次要研究目标
阿斯利康携手本土企业：从赋能到共创 重塑全球创新价值链
21世纪经济报道 · 11-07
阿斯利康携手本土企业：从赋能到共创 重塑全球创新价值链
阿斯利康携多方启动前列腺癌早筛公益科普行动
经济参考网 · 11-07
阿斯利康携多方启动前列腺癌早筛公益科普行动
美股异动丨阿斯利康涨约3.7%，Q3核心每股盈利超预期
格隆汇 · 11-06
美股异动丨阿斯利康涨约3.7%，Q3核心每股盈利超预期
美股异动 | 阿斯利康(AZN.US)盘前涨逾4% Q3核心每股盈利超预期
智通财经 · 11-06
美股异动 | 阿斯利康(AZN.US)盘前涨逾4% Q3核心每股盈利超预期
阿斯利康Q3总收入同比增长12% 核心每股盈利超预期
格隆汇 · 11-06
阿斯利康Q3总收入同比增长12% 核心每股盈利超预期
阿斯利康中国前三季度总营收同比增长5%
南方财经网 · 11-06
阿斯利康中国前三季度总营收同比增长5%
阿斯利康第三季度营收与利润超预期，维持全年业绩指引不变
老虎资讯综合 · 11-06
阿斯利康第三季度营收与利润超预期，维持全年业绩指引不变
加载更多
公司概况
公司名称：
阿斯利康
所属市场：
NASDAQ
上市日期：
--
主营业务：
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。
发行价格：
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":90.18,"timestamp":1764968400000,"preClose":90.03,"halted":0,"volume":5432911,"hourTrading":{"tag":"盘后","latestPrice":90.41,"preClose":90.18,"latestTime":"19:00 EST","volume":109209,"amount":9848997.8098,"timestamp":1764979239561},"delay":0,"floatShares":3088302520,"shares":3101451738,"eps":3.009339,"marketStatus":"休市中","change":0.15,"latestTime":"12-05 16:00:00 EST","open":90.69,"high":91.18,"low":90.065,"amount":491765046.10134,"amplitude":0.012385,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.009339,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":90.03,"dividendRate":0.017354,"preHourTrading":{"tag":"盘前","latestPrice":90.69,"preClose":90.03,"latestTime":"09:29 EST","volume":254243,"amount":23065059.70879,"timestamp":1764944999037},"postHourTrading":{"tag":"盘后","latestPrice":90.41,"preClose":90.18,"latestTime":"19:00 EST","volume":109209,"amount":9848997.8098,"timestamp":1764979239561},"volumeRatio":0.9548128487304486,"impliedVol":0.2454,"impliedVolPercentile":0.224},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2588737081","title":"港股异动 | 和铂医药-B(02142)午后涨近4% 公司与阿斯利康深化推进全球战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2588737081","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588737081?lang=zh_cn&edition=full","pubTime":"2025-12-02 13:54","pubTimestamp":1764654851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B午后涨近4%，截至发稿，涨3.15%，报13.76港元，成交额3342.44万港元。消息面上，和铂医药近日宣布，将更新与深化推进其与阿斯利康于2025年3月建立的全球战略合作。根据协议，阿斯利康将在未来四年内，每年持续向和铂医药提名研发项目，并获得这些项目的授权许可选择权，彰显双方合作关系的持续深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2417539215.USD","BK1574","LU2236285917.USD","AZN","LU0320765992.SGD","LU0109394709.USD","LU1829250122.USD","BK4588","BK4568","BK4585","LU0889565916.HKD","LU2456880835.USD","BK1161","LU2462157665.USD","BK4007","02142","BK1583"],"gpt_icon":0},{"id":"2586876290","title":"港股异动 | 和铂医药-B(02142)再涨超4% 与阿斯利康深化合作 共同研发新一代肿瘤生物疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586876290","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586876290?lang=zh_cn&edition=full","pubTime":"2025-11-27 10:18","pubTimestamp":1764209891,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B再涨超4%，截至发稿，4.25%，报14.22港元，成交额2784.77万港元。消息面上，和铂医药发布公告，宣布将更新与深化推进其与阿斯利康于2025年3月建立的全球战略合作。根据协议，阿斯利康将在未来四年内，每年持续向和铂医药提名研发项目，并获得这些项目的授权许可选择权，彰显双方合作关系的持续深化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","LU2462157665.USD","BK1583","LU0889565916.HKD","BK4588","LU2236285917.USD","LU0109394709.USD","BK4568","LU1829250122.USD","BK1161","LU2417539215.USD","LU2456880835.USD","AZN","BK1574","BK4585","02142","BK4007"],"gpt_icon":0},{"id":"2586715874","title":"阿斯利康投资20亿美元用于美国生物制品生产，同时RSV疫苗持久性与阿尔茨海默病药物试验面临挑战AstraZeneca Invests $2 Billion in US Biologics Manufacturing as RSV Vaccine Durability and Alzheimer’s Drug Trials Face Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2586715874","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586715874?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:28","pubTimestamp":1764080880,"startTime":"0","endTime":"0","summary":"报告显示，老年人接种RSV疫苗后保护效果的持久性正在随时间下降。The waning effectiveness of RSV vaccines raises concerns about long-term protection for older populations, prompting further evaluation of vaccine durability. AstraZeneca’s substantial investment underscores its commitment to expanding biologics capabilities within the U.S., with plans to bolster production infrastructure significantly.RSV疫苗效力的减弱引发了对老年人群长期保护的担忧，促使人们进一步评估疫苗的持久性。阿斯利康的巨额投资凸显了其致力于扩展在美国的生物制品能力，并计划大幅加强生产基础设施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511252230349519bdfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511252230349519bdfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","BK4532","NVO","BK4007","AZN","BK4585","LU2462157665.USD","BK4588","LU0889565916.HKD","LU1829250122.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","LU2417539215.USD","LU2236285917.USD","BK4599","LU2456880835.USD","LU0320765992.SGD","BK4568","LU0109394709.USD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2586341050","title":"港股异动 | 和铂医药-B(02142)涨近5% 与阿斯利康进一步拓展合作范围 开发ADC及T细胞衔接器疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341050","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586341050?lang=zh_cn&edition=full","pubTime":"2025-11-25 10:23","pubTimestamp":1764037381,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)涨近5%，截至发稿，涨4.92%，报13.62港元，成交额1542.11万港元。消息面上，11月24日，和铂医药-B发布公告，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","LU1829250122.USD","BK4007","BK1574","AZN","ADC","LU0109394709.USD","BK4588","LU0889565916.HKD","LU2417539215.USD","BK4080","LU0320765992.SGD","LU2236285917.USD","BK4585","BK1161","02142","BK4568","LU2456880835.USD","LU2462157665.USD","BK1583"],"gpt_icon":0},{"id":"2585245016","title":"阿斯利康：将在马里兰州投资20亿美元扩大美国业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2585245016","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585245016?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:33","pubTimestamp":1763976780,"startTime":"0","endTime":"0","summary":"阿斯利康表示，计划投资20亿美元扩大该公司在马里兰州的业务，这是该公司今年早些时候宣布的一项500亿美元美国投资的一部分。 该公司称，位于盖瑟斯堡的新临床生产设施将扩大公司在当地的业务版图。阿斯利康预计该基地将于2029年启用，创造100个工作岗位，保留400个职位，并创造1000个建筑相关工作岗位。7月份，该公司承诺在美国投入500亿美元用于药品生产和研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-24/doc-infypaav5656509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320765992.SGD","BK4585","LU0109394709.USD","LU2456880835.USD","LU2462157665.USD","LU1829250122.USD","LU0889565916.HKD","LU2236285917.USD","AZN","BK4588","BK4568","LU2417539215.USD","BK4007"],"gpt_icon":0},{"id":"2585436143","title":"和铂医药：与阿斯利康深化合作，共同研发新一代肿瘤生物疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2585436143","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585436143?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:28","pubTimestamp":1763944103,"startTime":"0","endTime":"0","summary":"南方财经11月24日电，据和铂医药消息，和铂医药将更新与深化推进其与阿斯利康于2025年3月建立的全球战略合作，共同发现和开发包括抗体偶联药物（ADC）和T细胞衔接器（TCE）在内的新一代生物疗法。根据协议，阿斯利康将在未来四年内，每年持续向和铂医药提名研发项目，并获得这些项目的授权许可选择权，彰显双方合作关系的持续深化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511243572260322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2417539215.USD","LU0109394709.USD","BK4568","LU2462157665.USD","LU2456880835.USD","02142","BK4588","LU0889565916.HKD","BK1583","AZN","BK1574","BK4007","LU1829250122.USD","LU2236285917.USD","BK4585","LU0320765992.SGD","BK1161"],"gpt_icon":0},{"id":"2585631430","title":"和铂医药-B与 AstraZeneca修订合作协议 合作范围进一步扩展","url":"https://stock-news.laohu8.com/highlight/detail?id=2585631430","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585631430?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:05","pubTimestamp":1763942700,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)公布，有关公司的间接全资附属公司和铂医药(上海)有限责任...和铂医药-B(02142)公布，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。追加内容本文作者可以追加内容哦 !","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080807977b515f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080807977b515f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","BK4007","AZN","LU1829250122.USD","BK4080","LU0320765992.SGD","BK4568","LU2456880835.USD","BK4585","BK4588","LU0889565916.HKD","LU2236285917.USD","BK4231","LU2462157665.USD","LU0109394709.USD","ADC"],"gpt_icon":0},{"id":"2585176975","title":"阿斯利康宣布投资20亿美元扩建马里兰州生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2585176975","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585176975?lang=zh_cn&edition=full","pubTime":"2025-11-22 15:31","pubTimestamp":1763796661,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2417539215.USD","BK4568","LU2462157665.USD","LU2456880835.USD","BK4588","LU0889565916.HKD","AZN","BK4007","LU2236285917.USD","LU1829250122.USD","BK4585","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2585171017","title":"阿斯利康盘中异动 大幅上涨3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585171017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585171017?lang=zh_cn&edition=full","pubTime":"2025-11-22 01:34","pubTimestamp":1763746481,"startTime":"0","endTime":"0","summary":"北京时间2025年11月22日01时34分，阿斯利康股票出现异动，股价急速上涨3.01%。截至发稿，该股报91.35美元/股，成交量386.393万股，换手率0.12%，振幅2.19%。机构评级方面，在所有31家参与评级的机构中，81%的券商给予买入建议，16%的券商给予持有建议，3%的券商给予卖出建议。阿斯利康股票所在的制药行业中，整体涨幅为1.78%。阿斯利康公司简介：1999年，瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122013442a7097e42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122013442a7097e42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU2236285917.USD","BK4585","LU0109394709.USD","LU2456880835.USD","LU0889565916.HKD","LU2462157665.USD","LU0320765992.SGD","AZN","BK4007","BK4568","BK4588","LU2417539215.USD"],"gpt_icon":0},{"id":"2585157775","title":"阿斯利康旗下Koselugo获美国FDA批准用于成人Ⅰ型神经纤维瘤病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157775","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585157775?lang=zh_cn&edition=full","pubTime":"2025-11-21 05:00","pubTimestamp":1763672400,"startTime":"0","endTime":"0","summary":"阿斯利康公司周四宣布，美国食品药品监督管理局已批准口服MEK抑制剂Koselugo （selumetinib）用于治疗有症状、无法手术切除的丛状神经纤维瘤 （PN）的成人神经纤维瘤病1型 （NF1）患者。 该批准基于KOMET III期临床试验结果，该试验显示成人患者中肿瘤大小减少的总体响应率为20%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-21/doc-infyccer0190747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0889565916.HKD","BK4588","BK4568","BK4585","LU2417539215.USD","LU0320765992.SGD","LU0109394709.USD","LU2456880835.USD","AZN","LU1829250122.USD","LU2462157665.USD","BK4007","LU2236285917.USD"],"gpt_icon":0},{"id":"2582364262","title":"巩固英股“第一大权重股”地位，医药巨头阿斯利康股价创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2582364262","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582364262?lang=zh_cn&edition=full","pubTime":"2025-11-11 21:49","pubTimestamp":1762868998,"startTime":"0","endTime":"0","summary":"11月11日，医药巨头阿斯利康英股股价一度涨至134.6英镑，创历史新高。作为富时100指数第一大权重股，其强势表现推动该指数同步上涨1.1%，亦创新高。股价上涨主要受前三季度营收与每股收益双位数增长的亮眼业绩支撑，此外美国药品定价协议缓解政策担忧，进一步提振市场信心。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3759137","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3759137","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2462157665.USD","BK4568","LU0889565916.HKD","BK4007","BK4588","BK1161","LU2236285917.USD","BK1574","AZN","09939","BK4585","LU0109394709.USD","LU2417539215.USD","LU2456880835.USD","LU1829250122.USD","BK1515","159938"],"gpt_icon":0},{"id":"2582594303","title":"阿斯利康股价再创新高 涨超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582594303","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582594303?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:36","pubTimestamp":1762850202,"startTime":"0","endTime":"0","summary":"阿斯利康股价再创新高 涨超2%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511113561034662.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511113561034662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","LU0889565916.HKD","BK4585","LU2462157665.USD","BK4568","AZN","LU1829250122.USD","BK4588","LU0109394709.USD","LU2236285917.USD","LU2417539215.USD","LU0320765992.SGD","LU2456880835.USD"],"gpt_icon":0},{"id":"2582780978","title":"阿斯利康(AZN)盘前升1.54% baxdrostat临床试验达成主要和次要研究目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2582780978","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582780978?lang=zh_cn&edition=full","pubTime":"2025-11-10 19:56","pubTimestamp":1762775802,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)盘前股价拉升，暂报85.88美元，涨1.54%。公司表示，其用于治疗难治性高血压患者的实验性药物baxdrostat 在一项三期临床试验中，已达到主要和次要研究目标。公司称，该药物总体耐受性良好，安全性与早期研究一致。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"294284","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2462157665.USD","BK4007","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","LU2236285917.USD","LU2456880835.USD","LU1829250122.USD","BK4585","AZN","BK4568","BK4588","LU2417539215.USD"],"gpt_icon":0},{"id":"2581884555","title":"阿斯利康携手本土企业：从赋能到共创 重塑全球创新价值链","url":"https://stock-news.laohu8.com/highlight/detail?id=2581884555","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581884555?lang=zh_cn&edition=full","pubTime":"2025-11-07 23:05","pubTimestamp":1762527905,"startTime":"0","endTime":"0","summary":"第八届中国国际进口博览会（进博会）于11月5日至10日在国家会展中心（上海）拉开帷幕，全球优质资源再度汇聚这场开放盛会。而在各大展区中，医疗器械及医药保健展区凭借超高的创新浓度，成为全场最受瞩目的焦点之一。作为与进博会共同成长的跨国药企代表，阿斯利康以八届“全勤生”的身份如约而至，用持续的投入与创新回应市场期待，也成为展区中极具代表性的亮点企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511073558574853.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511073558574853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2417539215.USD","LU2236285917.USD","AZN","LU0320765992.SGD","LU0109394709.USD","LU1829250122.USD","BK4588","BK4568","BK4585","LU0889565916.HKD","LU2456880835.USD","LU2462157665.USD","BK4007"],"gpt_icon":0},{"id":"2581300968","title":"阿斯利康携多方启动前列腺癌早筛公益科普行动","url":"https://stock-news.laohu8.com/highlight/detail?id=2581300968","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581300968?lang=zh_cn&edition=full","pubTime":"2025-11-07 18:25","pubTimestamp":1762511111,"startTime":"0","endTime":"0","summary":"7日，在第八届中国国际进口博览会举办期间，由阿斯利康和人民日报健康客户端共同发起的“早筛护‘前腺’，健康不掉线”前列腺癌早筛公益科普行动（以下简称“科普行动”）在阿斯利康展台正式启动。本次科普行动聚焦前列腺癌早筛与健康教育，旨在通过多维科普形式，提升公众的疾病认知，关爱中老年男性群体健康，支持推动前列腺癌防治关口前移，为“健康中国2030”癌症防治目标注入动能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511073558410853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0109394709.USD","LU2417539215.USD","LU1829250122.USD","BK4585","LU2236285917.USD","LU2456880835.USD","BK4588","LU0889565916.HKD","AZN","LU2462157665.USD","LU0320765992.SGD","BK4007","BK4568"],"gpt_icon":0},{"id":"2581097356","title":"美股异动丨阿斯利康涨约3.7%，Q3核心每股盈利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581097356","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581097356?lang=zh_cn&edition=full","pubTime":"2025-11-06 23:22","pubTimestamp":1762442530,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","LU0889565916.HKD","BK4568","BK4585","LU0320765992.SGD","LU2417539215.USD","LU2462157665.USD","LU1829250122.USD","LU0109394709.USD","AZN","BK4588","LU2236285917.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2581096749","title":"美股异动 | 阿斯利康(AZN.US)盘前涨逾4% Q3核心每股盈利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581096749","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581096749?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:47","pubTimestamp":1762436856,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，阿斯利康(AZN.US)盘前涨逾4%，报84.92美元。阿斯利康公布第三季度业绩，总收入同比增长12%至151.91亿美元，核心每股盈利为2.38美元，高于市场预期的2.27美元，受惠于重磅癌症及糖尿病药物销售理想。前九个月收入同比增长10%至432.36亿美元，核心每股盈利为7.04美元。公司重申全年收入将实现高单位数增长，以及核心每股盈利低双位数增长，与市场预期基本一致。公司计划宣布2025年全年股息为每股3.2美元，而去年为3.1美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","AZN","LU0109394709.USD","LU0320765992.SGD","LU2417539215.USD","LU1829250122.USD","LU2456880835.USD","BK4588","BK4585","BK4007","LU2462157665.USD","LU0889565916.HKD","LU2236285917.USD"],"gpt_icon":0},{"id":"2581054856","title":"阿斯利康Q3总收入同比增长12% 核心每股盈利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2581054856","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581054856?lang=zh_cn&edition=full","pubTime":"2025-11-06 16:37","pubTimestamp":1762418260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2236285917.USD","LU2417539215.USD","LU0889565916.HKD","LU2462157665.USD","LU0320765992.SGD","BK4568","AZN","BK4585","BK4007","LU0109394709.USD","LU2456880835.USD","LU1829250122.USD","BK4588"],"gpt_icon":0},{"id":"2581747059","title":"阿斯利康中国前三季度总营收同比增长5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581747059","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581747059?lang=zh_cn&edition=full","pubTime":"2025-11-06 16:09","pubTimestamp":1762416599,"startTime":"0","endTime":"0","summary":"南方财经11月6日电，2025年前三季度，阿斯利康业绩实现稳健增长。全球总营收同比增长11%，达到432.36亿美元。研发管线进展超过预期，自今年二月以来，阿斯利康已公布16项III期临床试验积极结果，其中5项为新药首次III期数据。与此同时，前三季度阿斯利康中国总营收同比增长5%，达到52.79亿美元，占全球收入的12%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511063557045121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN"],"gpt_icon":0},{"id":"1140094682","title":"阿斯利康第三季度营收与利润超预期，维持全年业绩指引不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1140094682","media":"老虎资讯综合","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140094682?lang=zh_cn&edition=full","pubTime":"2025-11-06 15:12","pubTimestamp":1762413159,"startTime":"0","endTime":"0","summary":"得益于核心癌症、心脏病及肾病药物的强劲销售，阿斯利康(AZN)周四盘前公布的第三季度业绩超出预期，该公司因此维持其全年业绩指引不变。消息公布后，阿斯利康夜盘几无变化。","market":"us","thumbnail":"https://community-static.tradeup.com/news/82a8d5a568f404ee362cec1bd92a07d8","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/82a8d5a568f404ee362cec1bd92a07d8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7f2763d4143b281511151cd3ee0fd9b1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康第三季度营收与利润超预期，维持全年业绩指引不变","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0274},{"period":"1month","weight":0.1113},{"period":"3month","weight":0.1038},{"period":"6month","weight":0.2374},{"period":"1year","weight":0.3354},{"period":"ytd","weight":0.3764}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.006892}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}